A Molecular Cancer study identifies the deubiquitylase USP7 as a regulator of immune signaling in microsatellite-stable colorectal cancer (MSS CRC). The authors show that USP7 activity suppresses antitumor immunity and that pharmacologic or genetic inhibition remodels the tumor immune microenvironment. Data include mechanistic experiments linking USP7 substrates to antigen presentation and T‑cell infiltration. The paper positions USP7 inhibition as a candidate combination with existing checkpoint blockade in MSS CRC, where immunotherapy responses are typically limited.